How these molecules work at the receptor level — GIP, GLP-1, and glucagon agonism, the single → dual → triple-agonist progression, and the pharmacokinetics that drive dosing. Educational reference only; nothing here is medical advice.
A patient initiates semaglutide (Ozempic) at 0.25 mg/week and reports nausea beginning on day 3 of the first injection. By week 4 at the same dose, the nausea has largely resolved. By week 12…
How retatrutide's triple-receptor mechanism (GIP, GLP-1, and glucagon) is studied for weight regulation, with trial-reported figures attributed to published sources. Investigational; not FDA-approved.